Literature DB >> 11000981

Mobilization of peripheral blood progenitor cells for autografting: chemotherapy and G-CSF or GM-CSF.

S Siena1, M Bregni, A M Gianni.   

Abstract

The mobilization of haematopoietic progenitor cells is a multifactorial process, still poorly understood at the molecular level. Mobilized haematopoietic progenitors, as defined by the expression of CD34 cell surface molecule, comprise heterogeneous subpopulations of cells committed to different haematopoietic lineages. Haematopoietic progenitors may be mobilized by chemotherapy alone, haematopoietic growth factors alone, or by chemotherapy plus haematopoietic growth factors. The choice of a mobilization regimen that allows an optimal yield of progenitors with a minimum number of leukaphereses should incorporate, in most patients, a disease-specific chemotherapeutic agent(s) plus a haematopoietic growth factor, to be continued until completion of harvest.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11000981     DOI: 10.1053/beha.1999.0005

Source DB:  PubMed          Journal:  Baillieres Best Pract Res Clin Haematol


  3 in total

Review 1.  Hematopoietic Stem Cells in Regenerative Medicine: Astray or on the Path?

Authors:  Albrecht M Müller; Sascha Huppertz; Reinhard Henschler
Journal:  Transfus Med Hemother       Date:  2016-07-26       Impact factor: 3.747

Review 2.  Current Developments in Mobilization of Hematopoietic Stem and Progenitor Cells and Their Interaction with Niches in Bone Marrow.

Authors:  Rudolf Richter; Wolfgang Forssmann; Reinhard Henschler
Journal:  Transfus Med Hemother       Date:  2017-05-29       Impact factor: 3.747

3.  Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients.

Authors:  P Quittet; P Ceballos; E Lopez; Z Y Lu; P Latry; C Becht; E Legouffe; N Fegueux; C Exbrayat; D Pouessel; V Rouillé; J P Daures; B Klein; J F Rossi
Journal:  Bone Marrow Transplant       Date:  2006-08       Impact factor: 5.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.